Focal segmental glomerulosclerosis 4, susceptibility to
MONDO:0012931Any focal segmental glomerulosclerosis in which the cause of the disease is a mutation in the APOL1 gene.
Also known as: APOL1 focal segmental glomerulosclerosis, focal segmental glomerulosclerosis 4, susceptibility to, focal segmental glomerulosclerosis caused by mutation in APOL1, glomerulosclerosis, focal segmental, 4, susceptibility to, FSGS4, end-stage renal disease, nondiabetic, susceptibility to, susceptibility to focal segmental glomerulosclerosis 4
7 clinical trials for this condition and its sub-types.
Follow this condition to get notified about new trialsBroader categories
-
New drug targets genetic kidney disease in landmark trial
Disease control Recruiting nowThis study tests an experimental drug called VX-147 in adults and children with a genetic form of kidney disease linked to the APOL1 gene. The goal is to see if the drug can reduce protein in the urine and protect kidney function. About 466 participants will receive either VX-147…
Phase 2/3 • Sponsor: Vertex Pharmaceuticals Incorporated • Aim: Disease control
Last updated Sep 09, 2026 17:00 UTC
-
New hope for APOL1 kidney disease: targeted drug enters Mid-Stage trial
Disease control Recruiting nowThis study tests an experimental drug called MZE829 in 56 adults with chronic kidney disease caused by a specific genetic risk (APOL1). The goal is to see if the drug can safely reduce protein leakage into urine, a sign of kidney damage. Participants will take the drug for 12 wee…
Phase 2 • Sponsor: Maze Therapeutics • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
New drug aims to plug leaky kidneys in APOL1 disease
Disease control Recruiting nowThis study tests an injectable drug called AZD2373 in 136 people with APOL1-mediated kidney disease, a genetic condition that mainly affects people of African descent. The goal is to see if the drug can reduce protein leakage into urine, a sign of kidney damage. Participants will…
Phase 2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Blood test may flag hidden kidney disease risk before damage is done
Diagnosis Recruiting nowThis study tests a blood-based genetic test designed to identify people who carry two copies of high-risk APOL1 gene variants, which are linked to a type of kidney disease. Around 2,000 participants who are already being considered for a separate treatment trial will provide a bl…
Sponsor: Almac Diagnostic Services LLC • Aim: Diagnosis
Last updated Jul 29, 2026 00:00 UTC